{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:11:07Z","timestamp":1792782667216,"version":"4.5.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e0 degli Studi di Padova","id":[{"id":"https:\/\/ror.org\/00240q980","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Pediatr"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Isavuconazole is a broad-spectrum antifungal agent approved for the treatment of invasive fungal infections (IFIs) in adults and, recently, in pediatric patients aged 1\u00a0year and older. Use in the pediatric setting remains limited, but available data indicate generally favorable safety and efficacy. This survey describes the institutional practices of use of isavuconazole across centers belonging to the Italian Association of Pediatric Hematology and Oncology (AIEOP). A 25-item web-based questionnaire, approved by the scientific board of the Infectious Working Group, was distributed to AIEOP centers between December 2024 and January 2025. The survey covered indications (prophylaxis and treatment), formulations and dosing, therapeutic drug monitoring (TDM), drug\u2013drug interactions, and management of adverse events. In 22\/49 (45%) responding centers, isavuconazole was available as capsules in 20\/22 (91%) and as an intravenous formulation in 17\/22 (77%). Primary prophylaxis was reported in 2\/22 (9%), while secondary prophylaxis was reported in 12\/22 (55%) centers, in patients diagnosed with possible (10\/22, 45%) or probable (12\/22, 55%) IFIs. In cases of\n                    <jats:italic>Aspergillus<\/jats:italic>\n                    spp. infection, 4\/22 (18%) centers considered isavuconazole for first-line treatment, 14\/22 (64%) for salvage treatment, and 5\/22 (23%) for combination treatment. In cases of mucormycosis, 4\/22 (18%) considered isavuconazole for first-line treatment, 9\/22 (41%) for salvage treatment, and 5\/22 (23%) for combination treatment. TDM was commonly adopted but varied across centers: 7\/22 (32%) performed TDM between days 5 and 7, 4\/22 (18%) only after the loading dose, and 5\/22 (23%) did not perform TDM.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:italic>Conclusion<\/jats:italic>\n                    : The results of this study show a widespread, off-label, heterogeneous use of isavuconazole in AIEOP centers. Such variability indicates the need for more standardized indications, dosages, and monitoring strategies.\n                    <jats:table-wrap>\n                      <jats:table>\n                        <jats:tbody>\n                          <jats:tr>\n                            <jats:td align=\"left\">\n                              What is known?\u2022\n                              <jats:italic>Isavuconazole is approved for invasive fungal infections in adults and, recently, in children aged =1 year, with favorable safety and efficacy, although pediatric experience remains limited.<\/jats:italic>\n                              \u2022\n                              <jats:italic>Real-world use of isavuconazole in pediatric hematology-oncology has not been systematically described.<\/jats:italic>\n                            <\/jats:td>\n                          <\/jats:tr>\n                          <jats:tr>\n                            <jats:td align=\"left\">\n                              What is new?\u2022\n                              <jats:italic>This national AIEOP survey shows widespread but heterogeneous use of isavuconazole, mainly as secondary prophylaxis and salvage therapy, with inconsistent therapeutic drug monitoring.<\/jats:italic>\n                              \u2022\n                              <jats:italic>Standardized indications, dosing, and monitoring strategies are needed in pediatric onco-hematology.<\/jats:italic>\n                            <\/jats:td>\n                          <\/jats:tr>\n                        <\/jats:tbody>\n                      <\/jats:table>\n                    <\/jats:table-wrap>\n                  <\/jats:p>","DOI":"10.1007\/s00431-026-07432-1","type":"journal-article","created":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T01:30:27Z","timestamp":1790127027000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A survey on the institutional practices of the use of isavuconazole in onco-hematological children, on behalf of the Infectious Working Group of AIEOP"],"prefix":"10.1007","volume":"185","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-9633-873X","authenticated-orcid":false,"given":"Lorenzo","family":"Chiusaroli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela","family":"Spadea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milena","family":"La Spina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Letizia Pomponia","family":"Brescia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Rosaria","family":"D\u2019Amico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica","family":"Ricci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Grazia","family":"Petris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marica","family":"De Pieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katia","family":"Perruccio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Pancaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Muggeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Colombini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Galaverna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Gasperini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Petroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Soncini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Rinieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Compagno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossella","family":"Mura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Baccelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelica","family":"Barone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Vittoria","family":"Micheletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Biffi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Don\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Cesaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,23]]},"reference":[{"issue":"6","key":"7432_CR1","doi-asserted-by":"publisher","first-page":"e254","DOI":"10.1016\/S1470-2045(20)30723-3","volume":"22","author":"AH Groll","year":"2020","unstructured":"Groll AH, Pana D, Lanternier F et al (2020) 8th European conference on infections in leukaemia: 2020 guidelines for the diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or post-haematopoietic cell transplantation. Lancet Oncol 22(6):e254\u2013e269","journal-title":"Lancet Oncol"},{"key":"7432_CR2","doi-asserted-by":"crossref","unstructured":"Autmizguine J, Guptill JT, Cohen-Wolkowiez M, Benjamin DK Jr, Capparelli EV (2014) Pharmacokinetics and pharmacodynamics of antifungals in children: clinical implications. Drugs 74(8):891\u2013909","DOI":"10.1007\/s40265-014-0227-3"},{"issue":"1","key":"7432_CR3","doi-asserted-by":"publisher","DOI":"10.1111\/myc.13654","volume":"67","author":"AH Groll","year":"2024","unstructured":"Groll AH, K\u00f6rholz K, Holterhus M, Lehrnbecher T (2024) New and emerging options for management of invasive fungal diseases in paediatric patients. Mycoses 67(1)","journal-title":"Mycoses"},{"key":"7432_CR4","doi-asserted-by":"publisher","DOI":"10.1111\/j.1439-0507.2011.02158.x","author":"B Moriyama","year":"2012","unstructured":"Moriyama B, Henning SA, Leung J et al (2012) Adverse interactions between antifungal azoles and vincristine: review and analysis of cases. Mycoses. https:\/\/doi.org\/10.1111\/j.1439-0507.2011.02158.x","journal-title":"Mycoses"},{"issue":"1","key":"7432_CR5","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1002\/pbc.22972","volume":"57","author":"ZD Pana","year":"2011","unstructured":"Pana ZD, Roilides E (2011) Risk of azole-enhanced vincristine neurotoxicity in pediatric patients with hematological malignancies: old problem\u2013new dilemma. Pediatr Blood Cancer 57(1):30\u20135","journal-title":"Pediatr Blood Cancer"},{"issue":"3","key":"7432_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/AAC.01783-19","volume":"64","author":"N Decembrino","year":"2020","unstructured":"Decembrino N, Perruccio K, Zecca M et al (2020) A case series and literature review of isavuconazole use in pediatric patients with hemato-oncologic diseases and hematopoietic stem cell transplantation. Antimicrob Agents Chemother 64(3):1\u201310","journal-title":"Antimicrob Agents Chemother"},{"key":"7432_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15010075","author":"H Elhence","year":"2023","unstructured":"Elhence H, Mongkolrattanothai K, Mohandas S et al (2023) Isavuconazole pharmacokinetics and pharmacodynamics in children. Pharmaceutics. https:\/\/doi.org\/10.3390\/pharmaceutics15010075","journal-title":"Pharmaceutics"},{"key":"7432_CR8","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkaf394","author":"N Mendoza-Palomar","year":"2025","unstructured":"Mendoza-Palomar N, Sim\u00f3 Nebot S, Roig-Soria L et al (2025) Real-life use of isavuconazole in Spanish children and adolescents. J Antimicrob Chemother. https:\/\/doi.org\/10.1093\/jac\/dkaf394","journal-title":"J Antimicrob Chemother"},{"key":"7432_CR9","unstructured":"European Medicines Agency (EMA). Cresemba [Internet]. 2025 [cited 2025 May 14]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/cresemba."},{"issue":"12","key":"7432_CR10","doi-asserted-by":"publisher","first-page":"e405","DOI":"10.1016\/S1473-3099(19)30312-3","volume":"19","author":"OA Cornely","year":"2019","unstructured":"Cornely OA, Alastruey-Izquierdo A, Arenz D et al (2019) Global guideline for the diagnosis and management of mucormycosis: an initiative of the european confederation of medical mycology in cooperation with the mycoses study group education and research consortium. Lancet Infect Dis 19(12):e405-21","journal-title":"Lancet Infect Dis"},{"key":"7432_CR11","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01783-19","author":"N Decembrino","year":"2020","unstructured":"Decembrino N, Perruccio K, Zecca M et al (2020) A case series and literature review of isavuconazole use in pediatric patients with hemato-oncologic diseases and hematopoietic stem cell transplantation. Antimicrob Agents Chemother. https:\/\/doi.org\/10.1128\/AAC.01783-19","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"7432_CR12","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1080\/10428194.2024.2416021","volume":"66","author":"J Styczynski","year":"2025","unstructured":"Styczynski J, Czyzewski K, Demidowicz E et al (2025) Isavuconazole in treatment of invasive fungal disease in children with malignancy or undergoing cellular therapy. Leuk Lymphoma 66(2):333\u2013336","journal-title":"Leuk Lymphoma"},{"key":"7432_CR13","doi-asserted-by":"publisher","DOI":"10.1097\/MPH.0000000000001787","author":"JA Ross","year":"2020","unstructured":"Ross JA, Karras NA, Tegtmeier B et al (2020) Safety of isavuconazonium sulfate in pediatrics patients with hematologic malignancies and hematopoietic cell transplantation with invasive fungal infections: a real world experience. J Pediatr Hematol Oncol. https:\/\/doi.org\/10.1097\/MPH.0000000000001787","journal-title":"J Pediatr Hematol Oncol"},{"issue":"2","key":"7432_CR14","doi-asserted-by":"publisher","first-page":"E143","DOI":"10.1097\/MPH.0000000000002812","volume":"46","author":"B Kunvarjee","year":"2024","unstructured":"Kunvarjee B, Siver M, Mathew S et al (2024) Characterization of the use and efficacy of isavuconazonium sulfate in a pediatric oncology and stem cell transplant population: a single institution retrospective review. J Pediatr Hematol Oncol 46(2):E143\u2013E146","journal-title":"J Pediatr Hematol Oncol"},{"key":"7432_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-025-02586-7","author":"L Pagano","year":"2025","unstructured":"Pagano L, Maschmeyer G, Lamoth F et al (2025) Primary antifungal prophylaxis in hematological malignancies. Updated clinical practice guidelines by the European Conference on Infections in Leukemia (ECIL). Leukemia. https:\/\/doi.org\/10.1038\/s41375-025-02586-7","journal-title":"Leukemia"},{"issue":"8","key":"7432_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/AAC.00290-21","volume":"65","author":"AC Arrieta","year":"2021","unstructured":"Arrieta AC, Neely M, Day JC et al (2021) Safety, tolerability, and population pharmacokinetics of intravenous and oral isavuconazonium sulfate in pediatric patients. Antimicrob Agents Chemother 65(8):1\u201312","journal-title":"Antimicrob Agents Chemother"},{"key":"7432_CR17","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofad468","author":"K Benedict","year":"2023","unstructured":"Benedict K, Gold JAW, Beekmann SE et al (2023) Antifungal therapeutic drug monitoring practices: results of an emerging infections network survey. Open Forum Infect Dis. https:\/\/doi.org\/10.1093\/ofid\/ofad468","journal-title":"Open Forum Infect Dis"},{"key":"7432_CR18","doi-asserted-by":"publisher","DOI":"10.3390\/jof11110797","author":"L Chiusaroli","year":"2025","unstructured":"Chiusaroli L, Spadea M, Liberati C et al (2025) Real-life use of posaconazole in clinical practice for onco-hematological children: a national survey by AIEOP Infectious Diseases Working Group. J Fungi. https:\/\/doi.org\/10.3390\/jof11110797","journal-title":"J Fungi"},{"issue":"6","key":"7432_CR19","doi-asserted-by":"publisher","first-page":"e70074","DOI":"10.1111\/myc.70074","volume":"68","author":"D Seidel","year":"2025","unstructured":"Seidel D, Pana ZD, Ebrahimi-Fakhari D et al (2025) Approaches to invasive fungal diseases in paediatric cancer centres: an analysis of current practices and challenges in Germany Austria Switzerland. Mycoses 68(6):e70074","journal-title":"Mycoses"},{"key":"7432_CR20","unstructured":"Study on theraputic drug monitoring and phamacokinetics of isavuconazole in children. NCT06440915. [Internet]. [cited 2025 Dec 2]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06440915?cond=isavuconazole&aggFilters=status:act%20rec%20not&rank=2&tab=table."}],"container-title":["European Journal of Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00431-026-07432-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00431-026-07432-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00431-026-07432-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:37:53Z","timestamp":1791920273000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00431-026-07432-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,23]]},"references-count":20,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["7432"],"URL":"https:\/\/doi.org\/10.1007\/s00431-026-07432-1","relation":{},"ISSN":["1432-1076"],"issn-type":[{"value":"1432-1076","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,23]]},"assertion":[{"value":"18 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was conducted according to the principles of Good Clinical Practice and the Helsinki Declaration. Ethical review, approval, and the informed consent statement were not required for the type of study. This was an anonymized survey of institutional practices, involving no patient-level data, patient contact, or identifiable information.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"772"}}